title: Quasi experimental designs in pharmacist intervention research.
abstract: Background In the field of pharmacist intervention research it is often difficult to conform to the rigorous requirements of the "true experimental" models, especially the requirement of randomization. When randomization is not feasible, a practice based researcher can choose from a range of "quasi-experimental designs" i.e., non-randomised and at time non controlled. Objective The aim of this article was to provide an overview of quasi-experimental designs, discuss their strengths and weaknesses and to investigate their application in pharmacist intervention research over the previous decade. Results In the literature quasi experimental studies may be classified into five broad categories: quasi-experimental design without control groups; quasi-experimental design that use control groups with no pre-test; quasi-experimental design that use control groups and pre-tests; interrupted time series and stepped wedge designs. Quasi-experimental study design has consistently featured in the evolution of pharmacist intervention research. The most commonly applied of all quasi experimental designs in the practice based research literature are the one group pre-post-test design and the non-equivalent control group design i.e., (untreated control group with dependent pre-tests and post-tests) and have been used to test the impact of pharmacist interventions in general medications management as well as in specific disease states. Conclusion Quasi experimental studies have a role to play as proof of concept, in the pilot phases of interventions when testing different intervention components, especially in complex interventions. They serve to develop an understanding of possible intervention effects: while in isolation they yield weak evidence of clinical efficacy, taken collectively, they help build a body of evidence in support of the value of pharmacist interventions across different practice settings and countries. However, when a traditional RCT is not feasible for logistical and/or ethical reasons researchers should endeavour to use the more robust of the quasi experimental designs.
authors.affiliation: Faculty of Pharmacy, A15, University of Sydney, Camperdown, NSW, 2006, Australia. ines.krass@sydney.edu.au.
authors.forename: Ines
authors.initials: I
authors.lastname: Krass
mesh_terms: D006801:Humans; D000070838:Pharmacy Research / Q000379:methods*; D010607:Pharmacy Service, Hospital; D012107:Research Design
keywords: Pharmaceutical care; Pharmacist intervention; Quasi experimental design; Research
references.citation: J Am Pharm Assoc (2003). 2009 Mar-Apr;49(2):192-9
references.pmid: 19289345
references.citation: BMC Med Res Methodol. 2006 Nov 08;6:54
references.pmid: 17092344
references.citation: J Am Pharm Assoc (2003). 2005 Mar-Apr;45(2):130-7
references.pmid: 15868754
references.citation: CMAJ. 2013 Oct 1;185(14):1228-32
references.pmid: 23959280
references.citation: J Eval Clin Pract. 2015 Feb;21(1):7-12
references.pmid: 24953287
references.citation: Diabet Med. 2007 Jun;24(6):677-83
references.pmid: 17523968
references.citation: Circulation. 2015 Jul 14;132(2):93-100
references.pmid: 26063762
references.citation: J Am Med Inform Assoc. 2006 Jan-Feb;13(1):16-23
references.pmid: 16221933
references.citation: J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):23-31
references.pmid: 18192127
references.citation: J Am Geriatr Soc. 2011 Jul;59(7):1238-45
references.pmid: 21649623
references.citation: Nephrol Dial Transplant. 2014 Aug;29(8):1597-607
references.pmid: 24914089
references.citation: J Asthma. 2015;52(6):638-45
references.pmid: 25539138
references.citation: Int J Clin Pharm. 2014 Apr;36(2):430-7
references.pmid: 24515550
references.citation: Aust J Rural Health. 2008 Apr;16(2):100-8
references.pmid: 18318852
references.citation: Drugs Aging. 2014 May;31(5):387-93
references.pmid: 24659397
references.citation: Pharmacotherapy. 2011 Jan;31(1):31-8
references.pmid: 21182356
references.citation: J Am Pharm Assoc (2003). 2008 Nov-Dec;48(6):722-30
references.pmid: 19019800
references.citation: J Asthma. 2013 Apr;50(3):302-9
references.pmid: 23270495
references.citation: BMJ Open. 2013 Sep 24;3(9):e003154
references.pmid: 24068762
references.citation: Pharmacotherapy. 2014 Oct;34(10):1033-42
references.pmid: 25142870
references.citation: Int J Clin Pharm. 2011 Feb;33(1):132-40
references.pmid: 21365405
references.citation: Ann Pharmacother. 2012 Jan;46(1):29-34
references.pmid: 22202497
references.citation: BMC Health Serv Res. 2004 Jun 07;4(1):11
references.pmid: 15182379
references.citation: Manag Care. 2012 Mar;21(3):44-54
references.pmid: 22471165
references.citation: J Am Pharm Assoc (2003). 2015 May-Jun;55(3):246-54
references.pmid: 26003155
references.citation: Ann Pharmacother. 2005 Nov;39(11):1911-7
references.pmid: 16219897
references.citation: BMC Health Serv Res. 2013 Dec 12;13:514
references.pmid: 24330781
references.citation: Patient Prefer Adherence. 2015 Jan 29;9:209-15
references.pmid: 25678779
references.citation: Br J Clin Pharmacol. 2001 Mar;51(3):257-65
references.pmid: 11298072
references.citation: Ann Pharmacother. 2010 Dec;44(12):1905-13
references.pmid: 21119098
references.citation: Perm J. 2012 Winter;16(1):28-33
references.pmid: 22529756
references.citation: J Clin Pharm Ther. 2011 Apr;36(2):144-51
references.pmid: 21366642
references.citation: Ann Pharmacother. 2012 Feb;46(2):183-91
references.pmid: 22318928
references.citation: Am J Health Syst Pharm. 2010 Feb 15;67(4):290-4
references.pmid: 20133534
references.citation: Pharmacotherapy. 2014 Nov;34(11):1141-50
references.pmid: 25283969
references.citation: Multivariate Behav Res. 2011 May;46(3):399-424
references.pmid: 21818162
references.citation: Am J Health Syst Pharm. 2008 Oct 1;65(19):1841-5
references.pmid: 18796426
references.citation: Diabetes Educ. 2015 Aug;41(4):459-65
references.pmid: 26009557
references.citation: Int J Clin Pharm. 2012 Apr;34(2):364-73
references.pmid: 22359183
references.citation: Ann Pharmacother. 2010 Dec;44(12):1877-86
references.pmid: 21119101
references.citation: Int J Clin Pharm. 2014 Oct;36(5):963-8
references.pmid: 24993458
references.citation: J Manag Care Pharm. 2013 Apr;19(3):228-36
references.pmid: 23537457
references.citation: Arch Intern Med. 2009 Nov 23;169(21):2003-10
references.pmid: 19933963
references.citation: J Am Pharm Assoc (2003). 2006 Mar-Apr;46(2):133-47
references.pmid: 16602223
references.citation: Br J Clin Pharmacol. 2012 Oct;74(4):573-80
references.pmid: 22607195
references.citation: Pharmacotherapy. 2006 Oct;26(10):1511-7
references.pmid: 16999661
references.citation: Res Social Adm Pharm. 2015 Jan-Feb;11(1):47-62
references.pmid: 24798710
references.citation: J Pharm Pract. 2011 Jun;24(3):332-8
references.pmid: 21676857
references.citation: J Eval Clin Pract. 2011 Feb;17(1):61-70
references.pmid: 20807295
references.citation: Health Policy. 2008 Dec;88(2-3):258-68
references.pmid: 18468713
references.citation: J Manag Care Spec Pharm. 2015 Jun;21(6):452-68
references.pmid: 26011547
references.citation: J Am Pharm Assoc (2003). 2009 Sep-Oct;49(5):623-7
references.pmid: 19748869
references.citation: J Am Pharm Assoc (2003). 2014 Sep-Oct;54(5):477-85
references.pmid: 25216877